CAR T-cell therapy for relapsed or refractory B-cell cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a locally made CAR T-cell therapy that targets CD19 on cancer cells. It is for children and young adults with certain B-cell cancers that have come back or not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 1 and 45 years old.
- You must have a B-cell cancer (like lymphoma or leukemia) that has come back or is not responding to treatment.
- Your cancer must have CD19 markers on the cells.
- You must have tried or cannot use all standard treatments that offer a chance of cure.
- You must have measurable disease present at screening.
- You and your doctor must agree to use effective birth control if needed and to not donate blood or organs during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving you a special kind of immune cell, called a CAR T cell, can help fight your B-cell leukemia or lymphoma that has come back or not gone away with standard treatments. The cells are made from your own blood and designed to attack the cancer cells that carry a marker called CD19.
This trial tests a new CAR T cell treatment for children whose B-cell acute lymphoblastic leukemia has come back or not responded to standard therapy. The goal is to see if this therapy is safe and can help control the cancer so a stem cell transplant may be possible.
This trial tests a CAR T-cell therapy that targets CD19 on cancer cells. It is for children whose B-cell acute lymphoblastic leukemia or aggressive B-cell non-Hodgkin lymphoma has come back or not responded to other treatments.
This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.
This trial tests a personalized immune-cell therapy (CAR T cells) made to attack B-cell cancers that have come back or did not respond to prior treatment. It aims to see how well the treatment works and how safe it is in children and young adults.
This trial tests whether specially designed immune cells (CAR T cells) that target CD19 can help adults whose B-cell acute lymphoblastic leukemia has not responded to standard treatments or has returned. The cells are made from your own blood and given back to you after a short chemotherapy preparation.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.